DaVita Inc. (DVA) Earnings Call Transcript & Summary

May 8, 2023

New York Stock Exchange US Health Care Health Care Providers and Services earnings 37 min

Earnings Call Speaker Segments

Nic Eliason

executive
#1

Thanks for joining us for this call about our first quarter results, and we're glad you're still following what's happening at our company. My name is Nic Eliason, and I serve as Group Vice President of Investor Relations. With me on the line today are our CEO, Javier Rodriguez, along with our CFO, Joel Ackerman. Before we go further, be aware that we might deliver forward-looking statements as defined under the federal securities laws. Every one of those statements carries both known and unknown risks and uncertainties, and because of that, actual outcomes could end up differing materially from what those forward-looking statements describe. If you'd like more specifics about such risks and uncertainties, take a look at the earnings press release for the first quarter along with the filings we've made with the SEC — that includes our latest annual report on Form 10-K, each quarterly report on Form 10-Q filed afterward, and any other documents we subsequently submit to the SEC. The forward-looking statements we make rest on information available to us right now, and we have no intention, and take on no obligation, to revise them, unless the law demands it. Also, a reminder that some non-GAAP financial measures will come up during this call. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand things over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thanks, Nic, and I appreciate everyone being on the call today. For DaVita, 2023 has gotten off to a solid beginning. We head into this year balancing cautious optimism regarding our capacity to carry out our plan against uncertainty around treatment volume in a difficult labor market; during Q1, we did well against our key metrics, and an improving macro environment gave our results a lift. Although certain outside uncertainties persist, if current trends continue, that would place us on track to produce strong results for the entire year. Before diving into the quarter's specifics, I want to go deeper on one piece of our long-term strategy, which is linking transitions of care via solutions for our patients at every stage of the kidney care continuum. That brings me to our clinical highlight involving CKD education. From time to time, we have shared updates about our community education program known as Kidney Smart. Building awareness through education within the kidney care community matters greatly, especially since one in seven American adults live with chronic kidney disease and most of them don't know it. Our Kidney Smart program is built to assist those patients in understanding and managing their kidney health, and nephrologists often recommend it as a go-to resource for educating patients. To help break down barriers to health equity, we have made these classes available in ten different languages; during 2022, more than 33,000 CKD patients took part in a Kidney Smart class, the highest figure ever across the program's 12-year history. In 2022, DaVita patients who participated in Kidney Smart classes had more than double the likelihood of selecting a home modality after consulting with their nephrologist and care team. Moving to how we performed financially. During Q1, our adjusted operating income came in at $352 million, and adjusted earnings per share were $1.58. As we mentioned in earlier quarters, we put a number of initiatives in place during the second half of 2022 to address pressures tied to lower volumes and higher costs. Those plans, together with strong operating rigor, produced positive results in the quarter, and some of the operating metrics that weighed on margin in 2022 are now starting to normalize. I'll begin with the largest source of Q1 outperformance, labor; we achieved solid progress on labor costs during the quarter, reflecting both operating diligence and an improvement in the broader labor environment. Like we've mentioned before, getting labor right comes down to balancing three things: wages going up, the money spent on contract workers, and what training costs. Across our clinics, our operators continued to boost their permanent staffing numbers, and that allowed us to bring contract labor spending down even more in Q1. Our goal for the whole year is to cut what we spend on contract labor in half versus last year, and we're ahead of schedule on that. Because we had more full-time employees and also more turnover, our training spend this quarter ran higher than usual — although it was still below last summer's peak. That's in line with what we anticipated. During the back half of the year, we're aiming for improved training efficiency; whether we actually get there hinges a lot on keeping our teammates on board, and that has traditionally tracked what's happening in the broader labor market. Now, on to treatment volume. Compared with the previous quarter, treatments per day were up about 1%, which put us above the middle of the range we'd forecast. The improvement came from net census gains, driven by a combination of higher admissions and lower deaths. Because 2022's excess mortality is now annualized, our expectation is still that total treatment volume will be lower than it was a year ago, and for the rest of this year we continue to build in excess mortality. All the same, the volume numbers we saw in Q1 give us reason for optimism. If things keep going the way they did in the first quarter, we'd expect to finish the year in the upper half of our volume guidance range, which runs from a 3% decline to flat compared with 2022. Now, two strategic items. DaVita and Medtronic came out on April 1st with word that Mozarc Medical is launching — a separate, newly formed device business devoted solely to breakthrough technologies for kidney health. Mozarc's existing offerings, along with what's in its R&D pipeline — everything from kidney access tech to sophisticated home dialysis and acute treatments — are meant to make the patient experience better overall and broaden access to care delivered at home. This funding underscores how serious we are about bringing about large-scale change in kidney care, and it lets us drive innovation alongside Medtronic, a worldwide leader in healthcare technology. Finally, I want to touch on integrated kidney care, or IKC. We continue to advance according to our business plan and continue to demonstrate that our approach to delivering care enhances the health and well-being of the patients we serve. Two examples come to mind. First, across our IKC program, more than 50% of patients receive what we call an optimal start — that is, they begin dialysis at home, or they start with appropriate vascular access already in place. Optimal starts reduce the need for costly, challenging hospitalizations and generally lead to lower continuing care costs over the months and years that follow. Next, additional information continues to show an encouraging disparity in hospital admission figures when comparing individuals enrolled in our IKC initiative against the broader group of people we serve. As we continue expanding that IKC operation—measured through the overall medical expenditure dollars within the program—our attention will remain on enhancing the net savings percentage while pursuing a care delivery approach that is cost-effective; put simply, when reviewing the operational measurements we consider most important, advancement is coming more quickly than we originally projected. Consequently, we are updating our guidance for adjusted operating income from a span of $1.4 billion-$1.6 billion to a span of $1.475 billion-$1.625 billion, and updating our adjusted earnings per share guidance from a span of $5.45-$6.95 to a span of $6.20-$7.30. Beyond the pandemic-related turbulence we’ve seen in employment, several other key elements will matter for the rest of this year: ongoing gains from the cost-reduction programs Joe will walk you through, and naturally, the work we’re continuing on the advocacy front to bring back patient benefit protections. At this point I’ll hand things to Joe so he can go deeper into our financial results and guidance.

Joel Ackerman

executive
#3

Appreciate that, Javier. I'll begin by offering a bit more color on how the first quarter came in, and after that I'll go deeper into what we're looking for over the balance of the year. To repeat what Javier noted, adjusted operating income for Q1 landed at $352 million. Adjusted EPS came in at $1.58. Free cash flow totaled $265 million. Taken as a whole, these results sat at the upper end of what we had expected for the quarter, and three factors drove that roughly in equal measure. One, solid operating results in the U.S. dialysis segment. Two, the timing of certain items within our IKC results. Three, a bit of ordinary favorable swing on a couple of cost lines that we don't anticipate repeating during the remaining months of the year. With that said, let me walk through some further specifics. To begin, U.S. dialysis treatments per day rose nearly 1% in Q1 versus Q4. As Javier pointed out, that reflected a larger patient census. Mistreatment rates stayed above where they sat before COVID and matched what we had anticipated. Revenue per treatment declined by $0.16 from one quarter to the next, which came from the usual seasonal effect of elevated patient responsibility, partly offset by January's start of annual Medicare fee-for-service rate increases, MA growth, and seasonal growth in acute treatments; on a non-GAAP basis, patient care cost per treatment fell $1.18 sequentially. The largest factors behind that shift were savings on pharmaceuticals stemming from our anemia management move to Mircera, lower contract labor spending, and favorable swing in health benefits and insurance costs. Those gains were partly offset by greater compensation costs and two fewer treatment days during the quarter. On a non-GAAP basis, G&A expenses declined $24 million from the prior quarter, mostly because of ordinary fluctuation in our G&A spending. IKC's adjusted OI for the quarter came in at roughly the same level as Q4 and ahead of what we had expected. Quarterly IKC results got a boost from revenue we had projected would arrive later in the year, along with a delay of certain expense items that we anticipate will be recognized in Q3 and Q4. Setting those items aside, IKC results matched our expectations. International adjusted operating income rose $12 million compared with Q4, split roughly evenly between foreign exchange and acquisition related expenses in Brazil during Q4. Turning to our capital structure, we finished the quarter with leverage of about 3.9x EBITDA. We repurchased no shares this quarter, since our priority remains returning to our target leverage ratio of 3x-3.5x EBITDA. During the final week of April, we completed a successful $2.75 billion refinancing of our revolving credit facility and Term Loan A, even with difficult conditions in the capital markets. Looking ahead, we continue to expect interest expense of $100 million-$110 million each quarter for the remainder of the year. Mozarc Medical, our partnership with Medtronic, launched on April first and will produce roughly $20 million of pre-tax losses below the OI line in Q2. That figure is smaller than what we previously communicated, reflecting timing shifts of certain standup costs. For the latter six months of this year, we continue to expect a negative effect of $15 million per quarter on other income. As we communicated earlier, we anticipate that Mozarc's OI will move toward breakeven over roughly the coming 3 years. When it comes to the savings programs we have discussed before, we remain on pace to deliver savings versus the prior year in the $125 million-$175 million range, in line with what we previously expected. The main drivers here are lower pharmaceutical costs along with the facility consolidation work we have underway. In Q1, we began our conversion to Mircera, and that will keep rolling out through the rest of the year; during Q1, we consolidated 20 centers, and at present we expect to consolidate an additional 40 to 50 centers across the remainder of the year. We keep seeing strong retention rates for both patients and teammates tied to these changes, since most patients at consolidated centers have moved to nearby DaVita facilities; that wraps up my prepared remarks for today. Operator, please open the line for Q&A.

Justin Lake

analyst
#4

Thank you. I appreciate the additional details. Joel, perhaps you could share some observations. You mentioned increased turnover and reduced temp labor expenses. What exactly is happening with turnover? What do you anticipate for the remainder of the year? How are labor costs trending compared to the headwind you previously described? Given the better-than-expected results this quarter, what are you forecasting for the rest of the year compared to Q1? If you achieve these figures, when do you expect to return to your target leverage ratio and, consequently, the ability to repurchase shares? Thanks.

Javier Rodriguez

executive
#5

That covers quite a bit. Allow me a moment to look this up, and then Joel can address any follow-up questions you have. Justin, it's Javier here. To begin with labor, we began providing additional detail when we experienced greater fluctuation in certain underlying metrics. I believe now is an opportune moment to bring up, as you requested, a larger figure. To ensure clarity regarding all metrics, when discussing SWBs, you include wages, productivity, benefits, training, and contract labor. Within wages, you can certainly drill down further. There's overtime, shift differential, and other elements, but let's focus on those five. During Q3 2022, we saw a surge in training and contract labor that we highlighted since they deviated from our typical figures. Looking ahead to now, we're concerned that individuals may not be adept enough with the calculations to determine how these five interact. Let me attempt to arrive at your figure, and if I don't, you can pose another question. Between 2018 and 2022, SWBs grew at a CAGR of about 2%; in 2022, which obviously included that anomaly we just discussed, the rate reached approximately 8% growth. For 2023 compared to 2022, we anticipate that figure, factoring in all those elements, will be closer to 4%-5% growth. Does that address your labor question, or would you like to ask something further?

Justin Lake

analyst
#6

Yeah, this is mainly about labor. What I’m attempting to work out is this: compared with that 4%-5%, if you keep going at this rate, where do you think you’ll land?

Joel Ackerman

executive
#7

Justin, I’d say we believe we are roughly $25 million ahead of the level we had expected on overall labor cost. If you consider our guidance raise at the midpoint of $50 million, I’d say half of it is labor and half of it is volume. That’s how I arrive at $25 million.

Justin Lake

analyst
#8

Joel, does that apply only to Q1? I'm sort of attempting to figure out, if this keeps up, whether that translates into $100 of improvement for you?

Joel Ackerman

executive
#9

Within the labor line, certain items showed up that, in our view, won't repeat. Those were favorable entries in areas such as benefits and workers comp, which I would remove when you're annualizing. A full-year figure would be 25. As for the path ahead, we anticipate wage pressure continuing as the year goes on. Contract labor will get somewhat better, though the bulk of the gains there have probably already materialized, since it occurred more quickly than anticipated; on productivity, little has changed; we're below the peak reached in the middle of last year, yet remain considerably higher than pre-COVID levels. At present, we're factoring in some improvement during the back half, while finishing the year still above pre-COVID levels; turnover that we're currently experiencing is really the main driver of that.

Justin Lake

analyst
#10

That helps. Joel, I’ll save my remaining questions for after the call. Thanks.

Joanna Gutierrez

analyst
#11

Hello, this is actually Nambia Gutierrez, filling in for Kevin. Thank you for taking the question. I just had one more brief question about labor. You mentioned that you anticipate ongoing wage pressure during the year. What level of wage inflation are you factoring in for this year, and what does that look like relative to last year and to pre-COVID levels? Thanks.

Javier Rodriguez

executive
#12

Yeah, I believe, you know, Justin already addressed this somewhat, so let me make sure we’re talking about the same thing. What we essentially said is that when you consider all of the variables, we expect SWBs to be 4%- 5% higher, 2023 over 2022. Does that respond to your question?

Joanna Gutierrez

analyst
#13

Yes. Thank you.

Javier Rodriguez

executive
#14

Thank you.

Joanna Gutierrez

analyst
#15

That covers everything. Thanks.

Analyst

analyst
#16

Hello, Thomas here, filling in for Andrew. Appreciate you fielding this. Javier, might you explain what drove the treatment growth outperformance during the quarter at a fundamental level, and also tell us how missed treatment rates are trending on a sequential basis? Thank you.

Javier Rodriguez

executive
#17

Appreciate the question. My preference is to look at treatments per day, and you'll notice that figure climbed roughly 90 basis points versus the prior quarter. Census gains are the main factor behind that, stemming from higher admissions during Q1, partly countered by ongoing excess mortality, which has fallen considerably compared with earlier years yet still sits above where it stood before COVID. As for mistreatment rates, the trend remains considerably above the pre-COVID level. It may fluctuate between quarters. Seasonality and various other factors play a role, but we continue to observe it sitting approximately 100 basis points above the level seen before COVID.

Analyst

analyst
#18

Understood, that's useful. One more quick question. I'd like to ask about the ESA changeover to Mircera. To be precise, is there any KPI you're able to provide for monitoring this transition, and can you say anything new regarding how quickly the rollout is proceeding? Thank you.

Javier Rodriguez

executive
#19

No disclosures exist on our side for that. The only thing I can say is the rollout is progressing exactly as we anticipated, and clinically speaking, the outcomes we were after are what we're observing. Everything is proceeding according to plan.

Analyst

analyst
#20

Great. Thanks again.

Javier Rodriguez

executive
#21

Thank you.

Peter Chickering

analyst
#22

Hello there, good afternoon, everyone. I have a follow-up regarding what Justin asked; about that $50 million increase in operating income, your comment was that one half came from labor and the other half from improved volumes. You mentioned nearly 60% additional lives were brought into IKC. I'm wondering, has anything shifted in terms of how that's performing relative to the guidance you gave before? Regarding the raised guidance, could you explain the path from $50 million of operating income to $100 million of free cash flow? Does that simply come from working capital, or are there other factors involved?

Javier Rodriguez

executive
#23

I'll handle the first portion, and Joel will address the second portion. Regarding IKC, as you might expect, this is a business that keeps expanding. Even though we are achieving very solid progress, it is unmistakably within the investment stage. Our view for the entire year remains unchanged; some timing effects were at play, which makes the figure appear somewhat stronger for the quarter to date than it will when looked at on an annualized basis. We remain aligned with the targets we previously communicated.

Joel Ackerman

executive
#24

Right, Peter, regarding free cash flow — like you mentioned, a boost in OI clearly supports that. There are two other factors: first, cash taxes are coming in better than our forecast, and second, working capital. As you can see, DSOs dropped quite a bit, so we expect some tailwind from that too for the year.

Peter Chickering

analyst
#25

Turning to Cigna IKC briefly — when you bring in 50, nearly 60% additional lives, that creates some headwind as those members ramp up. Any insight into how medical cost trends are behaving for the population you inherited at the start of the year? We've observed utilization surges elsewhere across healthcare. I'm just wondering how that 2022 cohort performed through Q1.

Javier Rodriguez

executive
#26

Correct, that matches what you're saying, and we share that view. Given all the disruption and fluctuation from COVID, it's tough to give a precise read. There isn't much to share. What we observe is savings arriving at the levels we anticipated. Our care model isn't as efficient as we'd like. We have to achieve greater scale, plus we must standardize many processes that currently remain manual; this is still a work in progress. We're expanding numerous capabilities we aspire to have, and we continue to anticipate reaching break even in 2026.

Peter Chickering

analyst
#27

Final thing from me, and this one you'll see coming. When we look at NAG growth, it's basically level compared to a year ago, though the direction is clearly much improved from what showed up across the prior few quarters. Baxter described a comparable return toward normal utilization. So I'd like whatever detail you can offer on the number of patients brought on during this quarter, and how that figure stacks up against, let's say, 2022 or the period before COVID. Also, anything further on where mortality stands among the patients currently on service?

Javier Rodriguez

executive
#28

Sure, Peter — I'll take you through a few figures. Net census growth for Q1 came to roughly 1,350 patients. Set that beside Q1 of 2022, when the figure was just shy of negative 500 patients — a swing of nearly 2,000 patients. The bulk of that gets accounted for by the shift in excess mortality, though part of it likewise comes from a stronger admit quarter now versus the same time a year ago. So we made headway on the mortality front as well as on admits.

Peter Chickering

analyst
#29

Then regarding the administrative side, I suppose to provide some context for the new ads in 1Q 2023 and what that looked like versus 1Q 2019, simply as a comparison against the pre-COVID period.

Javier Rodriguez

executive
#30

Were you to examine this with excess mortality taken out, the figures aren't right here with me, but what I can say is that this quarter was certainly above where Q1 of 2019 stood. Having said that, I'd want to be careful prior to us beginning to extrapolate this forward. What we have is a single quarter's worth of data; this measure has historically fluctuated from one quarter to the next, and I would prefer to hold off and observe what takes place across a few additional months before we're in a position to genuinely call this a trend.

Peter Chickering

analyst
#31

Okay, one final item about that. I apologize for continuing down this path, but you're examining the USRDS data. We look back across, as you know, a great number of years, and the rate at which end-stage renal disease occurs has stayed pretty steady for, well, close to 10 years. Do the indicators you're observing all suggest that incidence rates are going back to normal, or is it simply premature to make that determination right now?

Javier Rodriguez

executive
#32

Calling it is a bit premature. We have been examining and assessing every kind of data source, and drawing any conclusions isn't something we're prepared to do. You know, there's considerable movement upstream within the CKD population, especially involving COVID. We will take a look because, as you're aware, certain factors are causing progression to slow down. Conversely, other factors are extending life expectancy. At this stage, our math isn't pointing us toward any conclusion.

Peter Chickering

analyst
#33

That's my final item, and I'll quit asking questions after this one — at least right now — and it concerns mortality. I suppose I'd welcome whatever you can say about the level of normal mortality alongside excess mortality, plus how the two of those ought to be viewed as they carry on through the second half of the year. That's all from me.

Javier Rodriguez

executive
#34

For the quarter, excess mortality came to roughly 900 patients. Our forecast for excess mortality over the remaining portion of the year has been reduced a bit, yet we still anticipate a figure somewhere in the range of 2,500 to 3,000 patients, which is what sits within the midpoint of our guidance range.

Peter Chickering

analyst
#35

All right. Great. I'll stop there.

Javier Rodriguez

executive
#36

Thank you.

Gary Taylor

analyst
#37

Hello, and good evening. There are simply a couple of rapid figures I'd like to ask about. Joel, you brought up — or at minimum it appeared in the release — certain positive entries within G&A, one being an advocacy refund. I'm curious whether you might quantify that amount for us. Regarding IKC, I realize there are numerous shifting pieces involved, yet I was merely attempting to roughly reconcile how revenue fell by $4 million on a sequential basis versus 4Q, while you indicated there was some early revenue recognition there along with certain postponed expense. I'm just trying to roughly reconcile it, though it still includes a portion of early revenue recognition.

Joel Ackerman

executive
#38

Absolutely. $6 million is the ballot figure you're after. As for IKC, we observed roughly $20 million, with about half sitting in the revenue line and half in the expense line, which we had anticipated. We simply had anticipated it arriving later during the year. Concerning when that revenue lands, we typically consider IKC revenue to be weighted toward the back half of the year. When you consider the claims lags accumulating or reaching maturity, and then eventually the shared savings calculations being completed, that typically occurs during the back half of the year, and that is the point at which we'll record the shared savings dollars. That explains the drop you're seeing from Q4.

Peter Chickering

analyst
#39

Mm-hmm.

Joel Ackerman

executive
#40

I'd still describe it as a favorable surprise on timing.

Gary Taylor

analyst
#41

Got it. Perfect. Thank you.

Javier Rodriguez

executive
#42

Thank you, Gary.

Peter Chickering

analyst
#43

Okay. My apologies, everyone. There were just a few items I wanted to revisit with you. Treatment revenue essentially came in flat on a sequential basis, and the main driver there was the usual seasonal co-pays. So I suppose I have two things I'm wondering about. From managed care, what are you hearing regarding cost of living adjustments? And how should we be thinking about revenue per treatment as we move through the remainder of the year?

Javier Rodriguez

executive
#44

Thank you, Peter. There are a few points here; on the managed care negotiations, nothing has come up that we need to report. As a quick reminder, our contracts, as we've discussed, span multiple years. Each year, we renegotiate approximately 20% or so of our portfolio, and this year we aren't seeing anything out of the ordinary. During Q4 2022, we stated that we expected to achieve a year-over-year revenue per treatment increase of 2%-2.5% for 2023 versus 2022.

Peter Chickering

analyst
#45

All right, that's helpful. Regarding the savings that come from shutting down facilities, you closed 20 during this quarter. There was mention of merging another 40 to 50 locations. So how much in the way of cost reductions do you expect to actually achieve during 2023 as a result of those consolidations, purely from that item? And then what portion of that ought to carry over into 2024?

Javier Rodriguez

executive
#46

Right; we have not put a specific figure on it. It has consistently been described as a component of the $125-$175, though not the largest component. Mircera represents the largest component. That one will fall in 2023. Some portion will still carry over into 2024, but the bulk of it we will capture in 2023.

Peter Chickering

analyst
#47

All right. This is probably my final question. I may have missed this, but how much did contract labor cost during this quarter? What's your expectation for the remainder of the year? Can you give any detail on hiring and net hiring during the first quarter?

Javier Rodriguez

executive
#48

I believe our comment was that, during last year, if you recall, contract labor was running at approximately $100 million, and we indicated that for this year it would be half of that; now, as of today, we're updating that we're progressing at a better pace. That figure will come in closer to $35 million. Once more, I'd direct you back to the earlier part of this discussion, where we noted that the key thing is how all the variability across those metrics interacts, since naturally, training, productivity, wages, benefits and contract labor are all interconnected. That's the figure.

Peter Chickering

analyst
#49

The second thing, I suppose, is whether you can give us figures on how many people you brought on board during the quarter, what the net addition looked like once turnover is factored in, and how that ought to move across the year. You brought up the idea of training costs coming down as this batch starts to come on stream. It would help if you could put some numbers on that for us.

Javier Rodriguez

executive
#50

Sure. My mental model for the training costs goes like this. They hit their high point in the prior year, driven by two factors: more people leaving, plus our need to grow headcount on a net basis. Together those pushed training spending up. Looking at where we are right now, attrition is still running high. It has improved among certain categories of workers relative to others, yet it is still running high; our expectation is that training levels stay high until attrition declines, and we are building that into our plans for the back half of the year. We're either very near to, or already at, having every position filled. A portion of the training tied to rebuilding those staffing numbers has been completed by now, and that should reduce a chunk of the training costs compared with the high point we recorded in Q3 of last year.

Peter Chickering

analyst
#51

So when you mention that roughly 4% to 5% gain in SWB, how much of it would you say is more of a one-time thing — does it stem from the training expenses baked into the guidance that ought to phase out as we look ahead to 2024?

Javier Rodriguez

executive
#52

Not a large portion. Contract labor's shift is a far greater tailwind compared with 2022 than training productivity is; that's, well... One reason is that training productivity won't get better until the latter half of the year. Another reason is that early in 2022, training productivity remained low. We observed the spike during Q3, yet that lasted just a single quarter.

Peter Chickering

analyst
#53

All right, that's wonderful — many thanks, everyone. I really appreciate it.

Javier Rodriguez

executive
#54

Thank you, Peter.

Javier Rodriguez

executive
#55

Appreciate that, Michelle, and thanks to everyone for your questions. As I trust came through in today's discussion, we've got some favorable momentum as we begin the year. Should Q1's results turn out to be a trend that holds, we're enthusiastic about what that means for the people we treat, the members of our team, and how we perform financially in 2023 and afterward. Thanks to each of you for being on the call, and take care.

Operator

operator
#56

We appreciate your participation, and that brings us to the end of today's conference call. At this point, you're welcome to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.